Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AGN 195183 is a potent and selective agonist of RARα(Kd=3 nM) with improved binding selectivity relative to AGN 193836; no activity on RARβ/γ. IC50 value: 3 nM (Kd); 200 nM (EC80, RAR Trans.) Target: RARα agonist Compound 4(AGN-195183) inhibited the growth of breast cancer cell lines, and was inactive in an in vivo model of topical irritation. Compound 4 (AGN 195183) is currently in Phase I/IIA clinical trials in cancer patients. Compound 4 and ATRA inhibit growth of the human breast cancer cell lines, T-47D and SK-BR-3, however it does not cause the topical irritation induced by the RARa-selective retinoid, Am-580.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,470 | 5日内发货 | ||
5 mg | ¥ 2,490 | 5日内发货 | ||
25 mg | ¥ 8,620 | 8-10周 | ||
50 mg | ¥ 11,200 | 8-10周 | ||
100 mg | ¥ 17,400 | 8-10周 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,970 | 5日内发货 |
产品描述 | AGN 195183 is a potent and selective agonist of RARα(Kd=3 nM) with improved binding selectivity relative to AGN 193836; no activity on RARβ/γ. IC50 value: 3 nM (Kd); 200 nM (EC80, RAR Trans.) Target: RARα agonist Compound 4(AGN-195183) inhibited the growth of breast cancer cell lines, and was inactive in an in vivo model of topical irritation. Compound 4 (AGN 195183) is currently in Phase I/IIA clinical trials in cancer patients. Compound 4 and ATRA inhibit growth of the human breast cancer cell lines, T-47D and SK-BR-3, however it does not cause the topical irritation induced by the RARa-selective retinoid, Am-580. |
靶点活性 | RARα:3 nM (Kd) |
分子量 | 437.86 |
分子式 | C22H22ClF2NO4 |
CAS No. | 367273-07-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 62 mg/mL (141.60 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2838 mL | 11.4192 mL | 22.8384 mL | 57.0959 mL |
5 mM | 0.4568 mL | 2.2838 mL | 4.5677 mL | 11.4192 mL | |
10 mM | 0.2284 mL | 1.1419 mL | 2.2838 mL | 5.7096 mL | |
20 mM | 0.1142 mL | 0.571 mL | 1.1419 mL | 2.8548 mL | |
50 mM | 0.0457 mL | 0.2284 mL | 0.4568 mL | 1.1419 mL | |
100 mM | 0.0228 mL | 0.1142 mL | 0.2284 mL | 0.571 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AGN-195183 367273-07-2 Others AGN195183 AGN 195183 Inhibitor inhibitor inhibit